ASUS has achieved a significant milestone in its smart healthcare journey with the Thai Food and Drug Administration (FDA Thai) certifying its VivoWatch blood pressure app (FDA Thai no. 67-2-2-2-0009328). The certification marks the company’s first overseas medical software approval for its blood pressure app, underscoring its ambitions to establish a foothold in Southeast Asia’s growing digital healthcare market.

The blood pressure app, fully developed by ASUS, integrates with supported VivoWatch models, allowing users to monitor systolic and diastolic blood pressure and heart rate. Devices such as VivoWatch 6, VivoWatch 5, VivoWatch 5 AERO, and VivoWatch SP are expected to support the feature in Thailand by year-end.

“We are excited to bring our innovative health management solutions to the Thai market,” said Joe Hsieh, Chief Operating Officer and Global Senior Vice President of ASUS. “This certification from the Food and Drug Administration of Thailand is a testament to our dedication in creating reliable and effective health technology that empowers users to take control of their health.”

ASUS’s focus on mobile health (mHealth) extends beyond individual users. In Thailand, the company is partnering with high-end health examination centers and elderly care providers. These partnerships aim to integrate VivoWatch devices into long-term health data collection, enabling personalized health management and promoting remote care models.

Building on Taiwanese Success

ASUS’s expansion into Thailand builds on its existing mHealth initiatives in Taiwan, where its VivoWatch technology has been deployed in major hospitals to support continuous physiological monitoring. The Thai FDA certification represents a critical step in scaling this success internationally.

This move places ASUS among a growing number of tech firms leveraging Southeast Asia’s expanding healthcare market. With Thailand as its entry point, ASUS is positioning itself as a key player in digital healthcare solutions for the region.